C-Peptide Response and HLA Genotypes in Subjects With Recent-Onset Type 1 Diabetes After Immunotherapy With DiaPep277
Authors:
- Raffaella BuzzettiRBRaffaella Buzzetti
- Chiara GuglielmiCGChiara Guglielmi
- Paolo PozzilliPPPaolo Pozzilli
- on behalf of the DiaPep Trialists GroupOGon behalf of the DiaPep Trialists Group
Open Access
- 17 October 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 60 (11) , 3067-3072
Abstract
OBJECTIVE To investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting β-cell function evaluated by C-peptide secretion in recent-onset type 1 diabetic subjects. RESEARCH DESIGN AND METHODS Data were collected from type 1 diabetic subjects enrolled in multicenter phase II studies with a randomized, double-blind, and placebo-controlled design in whom fasting and stimulated C-peptide levels were measured. HLA genotypes were classified in high, moderate, and low risk categories. RESULTS A total of 146 subjects (aged 4.3 to 58.5 years) were enrolled, including 76 children (P for trend P < 0.01, and 0.53 ± 1.3 vs. −4.59 ± 1.5 nmol/L, P < 0.05, respectively). In the moderate risk genotype group, Δmaximal and AUC C-peptide values were significantly higher in DiaPep277-treated versus placebo-treated patients (P < 0.01 and P < 0.05, respectively). CONCLUSIONS This exploratory study demonstrates that type 1 diabetic adults with low and moderate risk HLA genotypes benefit the most from intervention with DiaPep277; the only subgroup with an increase of C-peptide at 12 months after diagnosis was the low risk DiaPep277-treated subgroup.Keywords
This publication has 29 references indexed in Scilit:
- The Rising Incidence of Type 1 Diabetes Is Accounted for by Cases With Lower-Risk Human Leukocyte Antigen GenotypesDiabetes Care, 2008
- Trends in High-Risk HLA Susceptibility Genes Among Colorado Youth With Type 1 DiabetesDiabetes Care, 2008
- Low‐risk HLA genotype in Type 1 diabetes is associated with less destruction of pancreatic B‐cells 12 months after diagnosisDiabetic Medicine, 2007
- Therapy with the hsp60 peptide DiaPep277™ in C‐peptide positive type 1 diabetes patientsDiabetes/Metabolism Research and Reviews, 2006
- Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signalingJournal of Clinical Investigation, 2006
- Genetic susceptibility to type 1 diabetesCurrent Opinion in Immunology, 2005
- The stages of type 1A diabetes: 2005Immunological Reviews, 2005
- Residual β-Cell Function and Male/Female Ratio Are Higher in Incident Young Adults Than in ChildrenDiabetes Care, 2005
- β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trialThe Lancet, 2001
- NOD Mouse Diabetes: The Ubiquitous Mouse Hsp60 is a β-Cell Target Antigen of Autoimmune T CellsJournal of Autoimmunity, 1996